The CanSino vaccine is currently undergoing Phase 3 trials and has been granted military approval in China, which is more limited than emergency authorisation.
Tianjin-based CanSino emerged as one of the fastest movers on a vaccine in May when it became the first firm to publish a full scientific study on its early human trials.
Initial talks held on the possibility of India entering the programme that was started in 2017 between France, Germany and Spain to ensure European sovereignty in defence and security.
COMMENTS